Amber Salzman, Ph.D., CEO of Epic Bio, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that Amber Salzman, Ph.D., chief executive officer of Epic Bio, was selected as one of 20 influential women in biopharma by Endpoints News. She will additionally be featured...
